Researcher.Life Logo

CNS Drugs : Impact Factor & More

eISSN: 1179-1934pISSN: 1172-7047

Key Metrics

CiteScore
9.8
Eigenfactor
0.005 - 0.01
Impact Factor
5 - 10
SJR
Q1Neurology (clinical)
SNIP
1.87
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on CNS Drugs

CNS Drugs Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • SJR SJR
Overview
Publisher ADIS INT LTD
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1994
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in CNS Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in CNS Drugs

Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.
  • 1 Mar 2026
  • CNS drugs
Zolpidem May Affect Glial Flow in Addition to Norepinephrine-Mediated Vasomotility of the Glymphatic System.
  • 1 Mar 2026
  • CNS drugs
Correction: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5‑HT2AR Antagonist (VVZ‑2471) in a Randomized, Double‑Blind, First‑in‑Human Study.
  • 26 Feb 2026
  • CNS drugs
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis
  • 26 Feb 2026
  • CNS Drugs
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
  • 21 Feb 2026
  • CNS drugs
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
  • 19 Feb 2026
  • CNS drugs
Multiple Sclerosis in Women: Impact of Different Life Stages on Treatment Decisions.
  • 1 Mar 2026
  • CNS drugs
Zolpidem May Affect Glial Flow in Addition to Norepinephrine-Mediated Vasomotility of the Glymphatic System.
  • 1 Mar 2026
  • CNS drugs
Correction: Evaluation of Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a Novel Dual mGluR5/5‑HT2AR Antagonist (VVZ‑2471) in a Randomized, Double‑Blind, First‑in‑Human Study.
  • 26 Feb 2026
  • CNS drugs
Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis
  • 26 Feb 2026
  • CNS Drugs
TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain.
  • 21 Feb 2026
  • CNS drugs
Ameliorating Seizures in Dravet Syndrome: A Review of Newly Approved and Investigational Drugs, RNA and Gene-Based Therapies.
  • 19 Feb 2026
  • CNS drugs

FAQs on CNS Drugs